Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Regal Pharmaceuticals

Pharmaceutical manufacturer · Rawat · Pakistan

Rawat/Islamabad pharmaceutical manufacturer operating since 2016 across solid, liquid, injectable, cephalosporin and nutraceutical dosage forms.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check9 Aug 2026Latest source-check date across this published portfolio
Latest effective price date1 Sep 2025Newest effective date among published current price records
Corporate profile evidence4 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Company type
Pharmaceutical manufacturer
Address
Plot 2-A, Street S-5, National Industrial Zone (RCCI), Rawat, Islamabad, Pakistan
Phone
+92 51 4499382-3
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
88%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000839 Regal Pharmaceuticals. · Punjab
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000839 59 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Contact Page Url source ↗ Logo Source Url source ↗ Profile Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx60public portfolio records represented
REG52unique registrations represented
IDX59indexed MedInfoBase presentations
SRC1additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR59current validated price records
G26generic molecules in indexed catalogue
DF5dosage-form groups
TA8therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage98%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage100%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixRegal PharmaceuticalsShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/regal-pharmaceuticalsGenerated 23 Sep 2026Anti-infectives43 · 73%Pain & musculoskeletal6 · 10%Vitamins, minerals & nutrition3 · 5%Reproductive & genitourinary2 · 3%CNS & mental health2 · 3%Fluids & supportive care1 · 2%Oncology & immunology1 · 2%Other therapeutic areas1 · 2%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioRegal PharmaceuticalsDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/regal-pharmaceuticalsGenerated 23 Sep 202659presentationsInjection19 · 32%Suspension18 · 31%Tablet11 · 19%Capsule6 · 10%Infusion5 · 8%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionRegal PharmaceuticalsCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/regal-pharmaceuticalsGenerated 23 Sep 202659comparable productsBelow peer median48 · 81%Near peer median6 · 10%Above peer median5 · 8%Company median price position-14.2%Lowest-price equivalents9Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsRegal PharmaceuticalsCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/regal-pharmaceuticalsGenerated 23 Sep 2026Pharmasol (Pvt) Ltd.22 shared85% overlapNeutro Pharma (Pvt.) Ltd.,22 shared85% overlapM/s. Genix Pharma (Pvt) Ltd.21 shared81% overlapZafa Pharmaceutical Laboratories (P…21 shared81% overlapS.J & G. Fazul Ellahie (pvt) limite…21 shared81% overlapNovaMed Pharmaceuticals(Pvt.)Ltd21 shared81% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives43 products · 73%
Pain & musculoskeletal6 products · 10%
Vitamins, minerals & nutrition3 products · 5%
Reproductive & genitourinary2 products · 3%
CNS & mental health2 products · 3%
Fluids & supportive care1 products · 2%
Oncology & immunology1 products · 2%
Gastrointestinal & hepatology1 products · 2%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins18 products · 31%
Macrolide antibacterials6 products · 10%
Analgesics / NSAIDs6 products · 10%
Oxazolidinone antibacterials5 products · 8%
Fluoroquinolone antibacterials4 products · 7%
Vitamins / minerals / hematinics3 products · 5%
Nitroimidazole anti-infectives3 products · 5%
First-generation cephalosporins3 products · 5%
Formulation footprint

Dosage forms

Injection19 products
Suspension18 products
Tablet11 products
Capsule6 products
Infusion5 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 TaksarCeftriaxone 7presentations 1 g, 2 g, 250 mg, 500 mg · Injection #2 LinzolLinezolid 5presentations 100 mg/5 mL, 200 mg, 400 mg, 600 mg · Suspension, Infusion, Tablet #3 AzoregAzithromycin 4presentations 200 mg/5 mL, 250 mg · Suspension, Capsule #4 RegcefCefixime 4presentations 100 mg/5 mL, 200 mg, 200 mg/5 mL, 400 mg · Suspension, Capsule #5 DerpaxCeftazidime 3presentations 1 g, 250 mg, 500 mg · Injection #6 RG-CinCephalexin 3presentations 250 mg, 250 mg/5 mL, 500 mg · Capsule, Suspension
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median4881% of comparable products
Near market median6within ±5% of median
Above market median58% of comparable products
Lowest-price equivalents9ties included
Company median price position -14.2% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Regtos 150 mgPolysaccharide iron complex · Capsule · 30's PKR 15.84/capsule-34.1% vs market median Clophen 50 mgClomifene citrate · Tablet · 3x10's PKR 29.86/tablet-28.8% vs market median Taksar 500 mgCeftriaxone · Injection · 1's PKR 244.87/vial/unit-25.5% vs market median Taksar 500 mgCeftriaxone · Injection · 1's PKR 244.87/vial/unit-25.5% vs market median Taksar 250 mgCeftriaxone · Injection · 1's PKR 145.48/vial/unit-24.3% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Pharmasol (Pvt) Ltd.257 products · 102 generics 22shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 22shared generics M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 21shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.245 products · 97 generics 21shared generics S.J & G. Fazul Ellahie (pvt) limited.193 products · 68 generics 21shared generics NovaMed Pharmaceuticals(Pvt.)Ltd187 products · 62 generics 21shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers51Distinct registrations among indexed, published, presentation-validated products only
Verified price observations59
Products with a verified price59
Products with multiple price observations0
Source records with multiple versions59
Latest portfolio source check9 Aug 2026
Latest effective price date1 Sep 2025
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

52 unique registration(s) · 59 indexed presentation(s) · 1 additional source-observed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Aqua Water for Injection 5 mL Injection 5mlx100's 082010 PKR 914.37 PKR 1.83/mL 9% below median
Azoreg Azithromycin 250 mg Capsule 10's 081979 PKR 448.72 PKR 44.87/capsule 9% below median
Azoreg Azithromycin 200 mg/5 mL Dry suspension 30ml 081982 PKR 520.13 PKR 17.34/mL 18% below median
Azoreg Azithromycin 200 mg/5 mL Dry suspension 15ml 081982 PKR 290.34 PKR 19.36/mL 9% below median
Azoreg Azithromycin 200 mg/5 mL Dry suspension 25ml 081982 PKR 447.25 PKR 17.89/mL 16% below median
Brofanic DS Ibuprofen 200 mg/5 mL Oral suspension 90ml 081990 PKR 105.58 PKR 1.17/mL 6% above median
Brofanic DS Ibuprofen 200 mg/5 mL Oral suspension 120ml 081990 PKR 132.52 PKR 1.10/mL 6% below median
Brofanic Liquid Ibuprofen 100 mg/5 mL Suspension 90ml 081989 PKR 96.84 PKR 1.08/mL 14% above median
Brofanic Liquid Ibuprofen 100 mg/5 mL Suspension 120ml 081989 PKR 129.12 PKR 1.08/mL 14% above median
Clophen Clomifene citrate 50 mg Tablet 3x10's 094222 PKR 895.93 PKR 29.86/tablet 29% below median
Clophen Clomifene citrate 50 mg Tablet 10's 094222 PKR 357.80 PKR 35.78/tablet 15% below median
Cynreg Hydroxychloroquine 200 mg Tablet 30's 099837 PKR 423.52 PKR 14.12/tablet Near median
Derpax Ceftazidime 500 mg Injection 1's 098462 PKR 207.42 PKR 207.42/vial/unit 15% below median
Derpax Ceftazidime 250 mg IV/IM injection 1's 098463 PKR 144.04 PKR 144.04/vial/unit 10% below median
Derpax Ceftazidime 1 g Injection 1's 098464 PKR 396.11 PKR 396.11/vial/unit 14% below median
Drol-D Cholecalciferol 5 mg/mL Injection 1mlx5's 082005 PKR 874.61 PKR 174.92/mL 9% below median
Drol-D Cholecalciferol 5 mg/mL Injection 1mlx1's 082005 PKR 182.22 PKR 182.22/mL 6% below median
Fluren Fluconazole 50 mg/5 mL Dry suspension 35ml 081984 PKR 347.86 PKR 9.94/mL 16% below median
Fygin Metronidazole (Benzoate) 200 mg/5 mL Suspension 60ml 081986 PKR 56.31 PKR 0.94/mL Near median
Fygin Metronidazole 200 mg/5 mL Suspension 120ml 081986 PKR 99.39 PKR 0.83/mL 10% below median
Fygin Metronidazole 500 mg IV infusion 100ml 081994 PKR 180.99 PKR 1.81/mL Near median
K-cin Amikacin 500 mg Injection 2mlx1s 082001 PKR 220.02 PKR 110.01/mL 9% below median
Linzol Linezolid 600 mg Tablet 12's 081957 PKR 4,233.92 PKR 352.83/tablet 10% below median
Linzol Linezolid 100 mg/5 mL Dry suspension 60ml 081983 PKR 579.77 PKR 9.66/mL 10% below median
Linzol Linezolid 200 mg IV infusion 1x100ml 081997 PKR 573.13 PKR 5.73/mL 21% below median
Linzol Linezolid 400 mg IV infusion 200ml 081998 PKR 662.58 PKR 3.31/mL 19% below median
Linzol Linezolid 600 mg IV infusion 300ml 081999 PKR 993.88 PKR 3.31/mL 15% below median
Lipsirox Valproic acid 250 mg Tablet 3x10's 097596 PKR 242.35 PKR 8.08/tablet 28% above median
Lipsirox Valproic acid 500 mg Tablet 3x10's 097597 PKR 386.26 PKR 12.88/tablet 38% above median
Lorex Levofloxacin 500 mg Tablet 10's 096626 PKR 599.21 PKR 59.92/tablet 24% below median
Natrox Anastrozole 1 mg Tablet 30's 092169 PKR 9,143.66 PKR 304.79/tablet 11% below median
Paedal Liquid Paracetamol 120 mg Suspension 100ml 081992 PKR 104.84 PKR 1.05/mL Near median
Paedal Liquid Paracetamol 120 mg/5 mL Suspension 120ml 081992 PKR 123.29 PKR 1.03/mL Near median
Reflox Ciprofloxacin 200 mg IV infusion 100ml 081993 PKR 175.97 PKR 1.76/mL 23% below median
Reflox Ciprofloxacin 500 mg Tablet 10's 096627 PKR 328.98 PKR 32.90/tablet 23% below median
Regcef Cefixime 100 mg/5 mL Dry suspension 30ml 098275 PKR 275.43 PKR 9.18/mL 12% below median
Regcef Cefixime 200 mg/5 mL Dry suspension 30ml 098276 PKR 344.96 PKR 11.50/mL 10% below median
Regcef Cefixime 200 mg Capsule 5's 098290 PKR 280.88 PKR 56.18/capsule 10% below median
Regcef Cefixime 400 mg Capsule 5's 098291 PKR 497.29 PKR 99.46/capsule 12% below median
Regtos Polysaccharide iron complex 150 mg Capsule 30's 095323 PKR 475.33 PKR 15.84/capsule 34% below median
Remox Moxifloxacin 400 mg Tablet 5's 092167 PKR 786.46 PKR 157.29/tablet 15% below median
Rethro Clarithromycin 125 mg/5 mL Dry suspension 60ml 081980 PKR 391.72 PKR 6.53/mL 11% below median
Rethro Clarithromycin 250 mg/5 mL Dry suspension 60ml 081981 PKR 648.77 PKR 10.81/mL 7% below median
RG-CinSource observed Cephalexin 150 mg/5 mL Dry suspension 60ml 098273Official source ↗ No indexed price — —
RG-Cin Cephalexin 250 mg/5 mL Dry suspension 60ml 098274 PKR 146.92 PKR 2.45/mL 20% below median
RG-Cin Cephalexin 250 mg Capsule 12's 098288 PKR 146.92 PKR 12.24/capsule 22% below median
RG-Cin Cephalexin 500 mg Capsule 12's 098289 PKR 288.08 PKR 24.01/capsule 22% below median
Setrox Ondansetron 8 mg/4 mL Injection 5x4ml 082003 PKR 4,281.95 PKR 214.10/mL 15% below median
Taksar Ceftriaxone 250 mg Injection 1's 098446 PKR 145.48 PKR 145.48/vial/unit 24% below median
Taksar Ceftriaxone 250 mg Injection 1's 098447 PKR 145.48 PKR 145.48/vial/unit 24% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Regal Pharmaceuticals — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/regal-pharmaceuticals/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.